Newlink Genetics Corporation
(NASDAQ : NLNK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading NLNK News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.78%71.011.0%$662.14m
AMGNAmgen Inc.
0.57%154.670.8%$509.58m
CELGCelgene Corporation
-0.85%112.661.0%$466.03m
ARIAARIAD Pharmaceuticals, Inc.
0.21%23.7516.4%$442.07m
BIIBBiogen Inc.
0.11%280.661.0%$398.14m
REGNRegeneron Pharmaceuticals, Inc.
-0.23%362.562.5%$365.69m
ALXNAlexion Pharmaceuticals, Inc.
-1.77%131.972.5%$347.73m
ILMNIllumina, Inc.
-0.52%159.743.8%$229.47m
CLVSClovis Oncology, Inc.
2.07%58.2917.9%$160.24m
INCYIncyte Corporation
-0.26%117.222.2%$158.22m
VRTXVertex Pharmaceuticals Incorporated
0.57%81.372.1%$144.14m
TSROTESARO, Inc.
-1.94%147.0015.0%$106.77m
IONSIonis Pharmaceuticals, Inc.
0.58%46.978.9%$101.63m
SRPTSarepta Therapeutics, Inc.
-4.59%32.6616.8%$101.57m
BMRNBioMarin Pharmaceutical Inc.
-1.78%84.624.9%$95.71m

Company Profile

NewLink Genetics Corp. is a biopharmaceutical company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.